Cargando…

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts

A xenobank of patient-derived (PDX) ovarian tumor samples has been established consisting of tumors with different sensitivity to cisplatin (DDP), from very responsive to resistant. As the DNA repair pathway is an important driver in tumor response to DDP, we analyzed the mRNA expression of 20 genes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guffanti, Federica, Fratelli, Maddalena, Ganzinelli, Monica, Bolis, Marco, Ricci, Francesca, Bizzaro, Francesca, Chilà, Rosaria, Sina, Federica Paola, Fruscio, Robert, Lupia, Michela, Cavallaro, Ugo, Cappelletti, Maria Rosa, Generali, Daniele, Giavazzi, Raffaella, Damia, Giovanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973859/ https://www.ncbi.nlm.nih.gov/pubmed/29872499 http://dx.doi.org/10.18632/oncotarget.25185

Ejemplares similares

Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
por: Ricci, Francesca, et al.
Publicado: (2019)

Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
por: Guffanti, Federica, et al.
Publicado: (2020)

Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy
por: Ricci, Francesca, et al.
Publicado: (2016)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
por: Ricci, Francesca, et al.
Publicado: (2017)

Predictive modeling of gene expression regulation
por: Regondi, Chiara, et al.
Publicado: (2021)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
por: Affatato, Roberta, et al.
Publicado: (2022)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
por: Chilà, Rosaria, et al.
Publicado: (2022)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Model
por: Previdi, Sara, et al.
Publicado: (2013)

The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs
por: Rulli, Eliana, et al.
Publicado: (2016)

Integrated molecular profiling of patient‐derived ovarian cancer models identifies clinically relevant signatures and tumor vulnerabilities
por: Lupia, Michela, et al.
Publicado: (2022)

Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair
por: Ganzinelli, Monica, et al.
Publicado: (2023)

Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents
por: Cesca, Marta, et al.
Publicado: (2013)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021)

Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
por: Fuso Nerini, Ilaria, et al.
Publicado: (2016)

Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
por: Chiappa, Michela, et al.
Publicado: (2022)

The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer
por: Guffanti, F., et al.
Publicado: (2016)

Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
por: Chilà, Rosaria, et al.
Publicado: (2014)

Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.
por: Giavazzi, R., et al.
Publicado: (1988)

In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models()()
por: Guffanti, Federica, et al.
Publicado: (2016)

The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions
por: Varone, Ersilia, et al.
Publicado: (2021)

Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines
por: de Oliveira, Sarah Franco Vieira, et al.
Publicado: (2016)

The ATRA-21 gene-expression model predicts retinoid sensitivity in CEBPA double mutant, t(8;21) and inv(16) AML patients
por: Bolis, Marco, et al.
Publicado: (2019)

Endoplasmic reticulum oxidoreductin 1‐alpha deficiency and activation of protein translation synergistically impair breast tumour resilience
por: Varone, Ersilia, et al.
Publicado: (2022)

Lipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancer
por: Garattini, Enrico, et al.
Publicado: (2016)

Ovarian cancer stem cells: still an elusive entity?
por: Lupia, Michela, et al.
Publicado: (2017)

Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma
por: Affatato, Roberta, et al.
Publicado: (2020)

Expression of genes involved in DNA repair and cell cycle checkpoint pathways in Triple Negative compared to Luminal A Breast Cancer: a molecular characterization
por: Ganzinelli, Monica, et al.
Publicado: (2012)

L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling
por: Giordano, Marco, et al.
Publicado: (2021)

Massive NGS data analysis reveals hundreds of potential novel gene fusions in human cell lines
por: Gioiosa, Silvia, et al.
Publicado: (2018)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

Trypsinogen 4 boosts tumor endothelial cells migration through proteolysis of tissue factor pathway inhibitor-2
por: Ghilardi, Carmen, et al.
Publicado: (2015)

Retinoic Acid Sensitivity of Triple-Negative Breast Cancer Cells Characterized by Constitutive Activation of the notch1 Pathway: The Role of Rarβ
por: Paroni, Gabriela, et al.
Publicado: (2020)

Platinum Resistance in Ovarian Cancer: Role of DNA Repair
por: Damia, Giovanna, et al.
Publicado: (2019)

Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
por: Restelli, Valentina, et al.
Publicado: (2015)

Resistance to glucose starvation as metabolic trait of platinum-resistant human epithelial ovarian cancer cells
por: Pastò, Anna, et al.
Publicado: (2016)

Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
por: Jones, M., et al.
Publicado: (1993)

Regulator of G-protein signaling 5 (RGS5) protein: a novel marker of cancer vasculature elicited and sustained by the tumor’s proangiogenic microenvironment
por: Silini, Antonietta, et al.
Publicado: (2011)

Glyphosate ingestion causing multiple organ failure: a near-fatal case report
por: Picetti, Edoardo, et al.
Publicado: (2017)

Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes
por: Ribeiro, Enilze, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ppnmqumg3lsn1m2b8gto7upgdd